Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages

  Naina, Harris V K ^a   Patnaik, Mrinal M ^a   Ali, Uzma A ^a   Chen, Dong ^a   Ashrani, Aneel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; CAPECITABINE; CYCLOPHOSPHAMIDE; D DIMER; FIBRINOGEN; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; FIBRINOLYSIS; HEMATURIA; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MASTECTOMY; METASTASIS; PRIORITY JOURNAL; BREAST TUMOR; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBRINOLYSIS; HUMANS; MIDDLE AGED; PROGNOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77951624650     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2502     Document Type: Article

References (12)

1. Menell JS, Cesarman GM, Jacovina AT, et al: Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340:994-1004, 1999 (Pubitemid 29157631)
2. Okajima K, Kohno I, Soe G, et al: Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res 66:717-727, 1992
3. Tagnon HJ, Whitmore WF Jr, Shulman NR: Fibrinolysis in metastatic cancer of the prostate. Cancer 5:9-12, 1952
4. Stephens RW, Brünner N, Jänicke F, et al: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52:99-111, 1998 (Pubitemid 29056088)
5. Look MP, Brünner N, Jänicke F, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116-128, 2002 (Pubitemid 34121291)
6. Manders P, Tjan-Heijnen VC, Span PN, et al: Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 101:486-494, 2004 (Pubitemid 38970599)
7. Chappuis PO, Dieterich B, Sciretta V, et al: Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 19:2731-2738, 2001 (Pubitemid 32441379)
8. Foekens JA, Peters HA, Look MP, et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60:636-643, 2000 (Pubitemid 30094561)
9. Malmstrom P, Bendahl PO, Boiesen P, et al: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19:2010-2019, 2001
10. Yamashita J, Inada K, Yamashita S, et al: Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer. Int J Clin Lab Res 21:227-230, 1992
11. Sallah S, Gagnon GA: Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 18:191-196, 2000 (Pubitemid 30164148)
12. Cooper DL, Sandler AB, Wilson LD, et al: Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer: Response to epsilon-aminocaproic acid. Cancer 70:656-658, 1992